Drawing for PARADIGM

USPTO serial 97583445

PARADIGM

Reviewed by CopyMark Law Group

Status 730Notice of Allowance
Filing date
Status date
Registration date
—
Examiner
PENDLETON, CAROLYN A
Law office
INTENT TO USE SECTION

What this means

The USPTO has issued a Notice of Allowance. To complete registration you generally need to file a Statement of Use or an extension request before the deadline.

Status 730: Status 730 means you filed the first six-month extension to delay filing a Statement of Use after a Notice of Allowance. You must file a Statement of Use or another extension before the new deadline.

Need help with PARADIGM?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Notice of Allowance, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $947*

Plus Government fees of $450

Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

PERRY J. VISCOUNTY

PERRY J. VISCOUNTY Latham & Watkins LLP650 TOWN CENTER DRIVE, SUITE 2000COSTA MESA, CA 92626United States

Goods and services

ClassDescriptionStatusFirst use
009Downloadable computer programs, and mobile device software for use by recruiting sites, principal investigators, clinical care teams, and/or patients for clinical trials, for use in planning, designing, implementing and/or managing clinical trials, and for use in conducting research, including patient journey analyses, cohort segmentation analysis, clinical trial design analysis, patient and population risk stratification analysis, safety and efficacy analysis, and/or health economics and outcomes research for clinical trials; application program interfaces, namely, downloadable software enabling software components to interact with each other for clinical trialsACTIVE—
035Business consulting and management in the field of data analytics for medical clinical trials, namely, management and compilation of databases in the field of medical clinical trials for business purposes; business consulting and management in the field of data analytics for medical clinical trials, namely, providing business information management services for such clinical trials; business information management in the field of data analytics for care coordination, and care navigation services in coordination with and/or on behalf of health plans, clinical trial sponsors, pharmaceutical manufacturers, physicians, hospital systems, patient advocacy organizations and/or other medical providers, all the foregoing in connection with medical clinical trialsACTIVE—
042Providing temporary use of online, non-downloadable software for use by principal investigators, recruiting sites, clinical care teams, and/or patients for clinical trials, for use in planning, designing, implementing and/or managing clinical trials and for use in conducting research, namely, patient journey analyses, cohort segmentation analysis, clinical trial design analysis, patient and population risk stratification analysis in connection with medical clinical trials, safety and efficacy analysis in connection with medical clinical trials, health economics and outcomes research, and/or comparative effectiveness analyses in connection with medical clinical trials; application service provider featuring application programming interface software for enabling software components to interact with each other in connection with medical clinical trials; providing use of online, non-downloadable software to health care providers for patient evaluation, care navigation, quality improvement, and clinical research in connection with medical clinical trials; providing use of online, non-downloadable software to health care providers, patients, advocacy organizations, and/or other parties involved in patient care to support the design, start up, conduct, and/or analysis of medical clinical trials; software as a service (SaaS) solutions featuring software for operating and managing clinical trials by third parties; software as a service (SaaS) services featuring software for providing medical and scientific research information in the field of pharmaceuticals and clinical trials; computer software platform as a service (PaaS) featuring computer software platforms for operating and managing medical clinical trials by third parties; computer software platform as a service (PaaS) featuring computer software platforms for providing data analytics for medical and scientific research information in the field of pharmaceuticals and clinical trials; providing data analytics for scientific research for medical purposes in connection with medical clinical trials; clinical trial support services in connection with data analytics, namely data analytics for scientific research in the nature of coordinating medical clinical trial research for others; virtual consulting services in connection with data analytics for medical and scientific research related to clinical trialsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 6, 2026EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 6, 2026EX1GSOU EXTENSION 1 GRANTED—
Oct 5, 2026EXT1SOU EXTENSION 1 FILED—
Oct 5, 2026EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 7, 2026NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Feb 23, 2026TMBNTTAB RELEASE CASE TO TRADEMARKS—
Feb 23, 2026OP.TOPPOSITION TERMINATED NO. 999999—
Feb 23, 2026OP.DOPPOSITION DISMISSED NO. 999999—
Jul 13, 2025ETOPEXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED—
Jul 11, 2025OP.IOPPOSITION INSTITUTED NO. 999999—
Feb 11, 2025ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Jan 14, 2025NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jan 14, 2025PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 8, 2025NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Dec 18, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 22, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 22, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 22, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 23, 2024ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Oct 1, 2024XELGAPPLICATION EXTENSION GRANTED/RECEIPT PROVIDED—
Oct 1, 2024XELRAPPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED—
Sep 26, 2024TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Sep 26, 2024ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 26, 2024REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Sep 26, 2024CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Sep 26, 2024COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Jul 9, 2024GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 9, 2024GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 9, 2024CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 22, 2024TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Apr 22, 2024CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 22, 2024TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 9, 2024XELGAPPLICATION EXTENSION GRANTED/RECEIPT PROVIDED—
Feb 9, 2024XELRAPPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED—
Nov 9, 2023GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 9, 2023GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 9, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 6, 2023TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 5, 2023CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 5, 2023TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 5, 2023GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 5, 2023GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 5, 2023CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 22, 2023DOCKASSIGNED TO EXAMINER—
Sep 14, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Sep 12, 2022NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance